Sign in
Taking people in South AfricaPhase 2

Tests new and existing drugs for newly diagnosed drug-sensitive lung tuberculosis

Compares new tuberculosis drug combinations with standard treatment in adults with lung tuberculosis.

Key facts

Who runs it
Michael Hoelscher
Where
Cape Town and Port Elizabeth, South AfricaSee the 3 sitesAlso in 5 other countries, 7 sites
Trial code
Registry title
PanACEA - STEP2C -01
Status
Recruiting
Phase
Phase 2
People taking part
390 people, planned
Started
14 Apr 2023
Expected to end
30 Dec 2027
Type of study
Interventional, 7 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • BTZ-043
  • Rifampicin
  • Isoniazid
  • Pyrazinamide
  • Moxifloxacin
  • Alpibectir (GSK3729098)
  • Ganfeborole (GSK3036656)
  • Delpazolid (LCB01-0371)
  • Pretomanid (Pa)
  • Ethambutol (E)
  • Ethionamide
Record updated
7 October 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with newly diagnosed pulmonary tuberculosis (TB) that responds to standard TB drugs, with TB bacteria found in a sputum sample.

Age
18 to 65 years
Sex
All sexes
Disease stage
Newly diagnosed, drug-sensitive TB of the lungs, with TB bacteria seen in sputum (at least 1+ on microscopy and/or a medium or high GeneXpert result). A chest X-ray from the last 2 weeks must show changes consistent with TB.
Earlier treatment
No earlier TB treatment. People with past TB can join if treatment was completed, it worked well, and the last dose was more than 3 months ago. No other trial drug in the last 2 months.
Biomarker or test result
Rapid test (such as GeneXpert or HAIN MTBDR plus) confirming the TB responds to rifampicin (RIF) and isoniazid (INH). Body weight 40 to 90 kg (88–198 lb).

Main reasons for not taking part

  • Pregnant, breast-feeding or planning pregnancy
  • HIV with CD4 count below 220 cells/mm3
  • Serious heart, lung, liver, kidney or mental health problems, or TB outside the lungs
  • Abnormal heart tracing (ECG), such as QTcF above 450 milliseconds
  • Liver or kidney blood tests outside the limits set in the record

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Provide written, informed consent prior to all trial-related procedures including HIV testing
  • Male or female, aged between 18 and 65 years, inclusive
  • Body weight (in light clothing and with no shoes) between 40 and 90 kg, inclusive
  • Newly diagnosed, previously untreated, drug susceptible pulmonary TB: presence of MTB complex and rapid molecular tests result confirming susceptibility to RIF and INH such as GeneXpert and/or HAIN MTBDR plus. Participants who had a previous history of TB may be enrolled in this trial, if they:; had a good treatment response in the opinion of the investigator; i.e. TB symptoms improved sufficiently or resolved suggesting a cure of the past episode; AND; no persistent microbiological positivity is seen (in case microbiological results are available); AND - their treatment course was completed AND; the last dose of treatment was more than 3 months ago
  • A chest X-ray (no older than 2 weeks) which shows abnormalities that, in the opinion of the Investigator, are consistent with TB
  • Sputum positive on microscopy from concentrated sputum for acid-fast bacilli (at least 1+ on the IUATLD/WHO scale) AND/OR positive GeneXpert MTB/RIF Ultra® semi-quantitative result "medium" or "high" on at least one sputum sample
  • The participant understands the interaction between the study drugs and certain foods and is willing to forgo the consumption of those foods for the period of study medication
  • The participant is not of child-bearing potential or is willing to use effective methods of contraception when engaging in heterosexual intercourse, as defined below:; Non-childbearing potential:; Female participant/sexual partner of male participant: Bilateral oophorectomy, and/or hysterectomy or bilateral tubal ligation more than 12 months ago and/or has been postmenopausal with a history of no menses for at least 12 consecutive months and confirmed by a FSH test; Male participant/sexual partner of female participant: Vasectomised or has had a bilateral orchidectomy minimally three months prior to screening iii. Male participants having a pregnant female partner or a male sexual partner: At least one barrier method has to be used in this case; Effective contraception methods: i. Female participants: Two methods, including methods that the participant's sexual partner(s) use. At least one must be a barrier method. Contraception must be practised for at least until 12 weeks after the last dose of experimental treatment. For stage 3, female participants of child-bearing potential must have used contraception if any sexual intercourse has occurred after last menses or within the last 3 weeks (whichever is later) before participation, and agree to use non-user dependent contraception: depo-provera injection* or an intrauterine device additional to one barrier method; *Including a back-up method of contraception for at least 7 days to prevent unintended pregnancy if injection has been administered within the first 5 days of their menstrual cycle. Otherwise, a back-up barrier method of contraception is required for one month to prevent unintended pregnancy; Male participants: Two methods, including methods that the participant's female sexual partner(s) use. At least one must be a barrier method. Effective contraception must be ensured for at least 12 weeks after the last dose of experimental treatment

Who cannot take part

  • The participant has a known intolerance to any of the study drugs or concomitant disorders or conditions for which study drugs or standard TB treatment are contraindicated
  • Restricted medication:; Treatment with any other investigational drug within 2 month prior to enrolment or enrolment into other clinical (intervention) trials during participation; Previous anti-TB treatment with drugs active against MTB within the last 3 months prior to screening; Unable or unwilling to abide by the requirements regarding restricted medication or have taken restricted medication. Restricted medication includes the following drug classes, with relevant timing of intake, and possible exceptions. Exceptions may be permissible after discussion with the sponsor medical expert
  • Poor general condition where delay in treatment cannot be tolerated or death within four months is likely
  • The participant is infected with HIV with a CD4 count <220 cells/mm3. If >220 cells/mm3, participants will be included only if any of the following is applicable:; The participant is antiretroviral (ARV) naïve and able to postpone commencing HIV treatment for 2 months after the trial has started and then restrict regimens to those mentioned in section on ARVs or; The participant is ARV experienced (has been on ARV´s a minimum of 5 months), AND: ARV treatment is compliant to, or can be modified as described in the section on Antiretroviral Therapy
  • The participant has a history of, or current evidence of clinically relevant cardiovascular metabolic, gastrointestinal, neurological, hepato-biliary, renal, psychiatric or endocrine diseases, malignancy, or any other condition that will influence treatment response, study adherence or survival in the judgement of the investigator, especially:; Neuropathy, or significant psychiatric disorder like depression or schizophrenia; especially if treatment for those has ever been required or is anticipated to be required b. Evidence of clinically significant extra-pulmonary TB (e.g. miliary TB, TB meningitis, but not limited lymph node involvement) c. Serious lung conditions other than TB, or significant respiratory impairment in the discretion of the investigator d. Uncontrolled diabetes mellitus or diabetes mellitus receiving/requiring treatment with metformin or sulfonylureas e. Cardiovascular disease such as myocardial infarction, heart failure, coronary heart disease, arrhythmia, tachyarrhythmia, or pulmonary hypertension f. Uncontrolled arterial hypertension (systolic blood pressure ≥150 mmHg and/or diastolic blood pressure of ≥95 mmHg on two occasions during screening. An attempt at antihypertensive treatment during the screening period is permitted); Long QT syndrome or family history of long QT syndrome or family history of sudden death of unknown or cardiac-related cause h. Alcohol, regular opiate, or other drug abuse that is sufficient to significantly compromise the safety or cooperation of the participant, that includes substances prohibited by the protocol or has led to significant organ damage at the discretion of the investigator; AND/OR any abuse of methamphetamine; History of optic neuropathy j. Vitiligo
  • Any of the following laboratory findings at screening:; Serum amino aspartate transferase (AST) and/or alanine aminotransferase (ALT) >3x the upper limit of normal (ULN), b. Serum alkaline phosphatase or y-glutamyl transferase > 2.5x the ULN, c. Serum total bilirubin level >1.5x the ULN d. Estimated creatinine clearance -eCrCl (using the CKD-EPI 2021 creatinine formula):; Stage 1: Lower than 30 ml/min); Stage 2: Lower than 30ml/min or lower than 60 ml/min in participants living with HIV; Stage 3: Lower than 80ml/min e. Proteins in urine dipstick >=2+ f. Haemoglobin level <7.0 g/dl g. Platelet count <50,000/mm3, h. Serum potassium below 3 mmol/l, persisting after correction
  • <!-- -->
  • Circumstances that raise doubt about free, unconstrained consent to study participation (e.g., person in detention or person with mental disability)
  • Circumstances (in the opinion of the investigator) that raise doubt about ability to complete the follow-up during the study period
  • The participant is pregnant or breast-feeding or planning to become pregnant in the study period
  • ECG findings in the screening ECG: (one or more):; QTcF of >450 milliseconds; Atrioventricular (AV) block with PR interval > 200 milliseconds; QRS complex > 120 milliseconds; Any other changes in the ECG that are clinically relevant as per discretion of the investigator

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

This trial is currently available in South Africa.

Also in 5 other countries, 7 sites

  • TASK Applied Sciences Clinical Research CentreCape Town, South AfricaContact: Fairoez Ryklief, DrTaking people
  • University of Cape Town Lung InstituteCape Town, South AfricaContact: Rodney Dawson, Dr.Not yet recruiting
  • Isango Lethemba TB Research Unit. Clinical HIV Research Unit (CHRU), Wits Health Consortium.Port Elizabeth, South AfricaContact: Kinita Naidoo, Dr.Not yet recruiting

About the trial

What the trial wants to find out

This is a phase 2B/C, open label platform study that will compare the efficacy, safety of experimental regimens with a standard control regimen in participants with newly diagnosed, drug sensitive pulmonary tuberculosis.

Read full original descriptionShow less

In stage 1, participants will be randomly allocated to the control or one of the 2 rifampicin-containing experimental regimens in the ratio 1:1:1.

In stage 2, the experimental arm 4 containing BTZ-043 will be added. The allocation ratio will be changed to co-enrol the remaining participants in arms 1- 3 simultaneously with arm 4 in a ratio of 1:1:1:2. When arms 1-2 are fully enrolled and arm 4 is not, further participants will be randomized 1:1 to control and experimental arm 4. Not all countries will participate in stage 2.

In stage 3, participants will be allocated in parallel to control arm treatment (now designated arm 7) or the experimental arms 5 and 6, favouring arm 5, 2:1:1 over arms 6 and control. This stage will start after completion of recruitment in the stages 1 and 2. Enrolment of participants into arm 5 will proceed following review of data from the ENABLE/UNITE-03 (NCT06748937), non-clinical safety data and after endorsement by the DSMB. Thus, arm 5 recruitment might start after arms 6 and 7, which may require an increase in the control arm sample size to ensure controls are recruited concomitantly.

The 7 groups in the trial

  • Arm 1 (Stage 1)Treatment being tested

    Rifampicin 2100mg, isoniazid 300mg, pyrazinamide 1600mg moxifloxacin 600mg; given once daily for 17 weeks (R2100HZM600)

    Treatment: Rifampicin, Isoniazid, Pyrazinamide, and Moxifloxacin

  • Arm 2 (Stage 1)Treatment being tested

    Rifampicin 2100mg, isoniazid 300mg, pyrazinamide 2000mg/2400mg, moxifloxacin 600mg; given once daily for 12 weeks (R2100HZoptM600)

    Treatment: Rifampicin, Isoniazid, Pyrazinamide, and Moxifloxacin

  • Arm 3Existing treatment, for comparison

    Stage 1: control arm (2HRZE-4RH) Stage 2: continuation of control-arm from STAGE 1 (2HRZE-4RH)

    Treatment: Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol (E)

  • Arm 4 (Stage 2)Treatment being tested

    Rifampicin, Isoniazid, and Pyrazinamide in weight-banded standard dosages with BTZ-043 1,000mg; given once daily for 17 weeks (RHZT), then rifampicin and isoniazid in weight-banded dosages; given once daily for 9 weeks (RH)

    Treatment: BTZ-043, Rifampicin, Isoniazid, and Pyrazinamide

  • Arm 5 (Stage 3)Treatment being tested

    Alpibectir (GSK3729098) 45mg, ethionamide 500mg (A/Eto) with possibility of lower alpibectir and Eto doses based on emerging clinical data, from the ENABLE study \[ Clinical Trials gov NCT06748937\] and non-clinical data and endorsed by the GSK Global safety board, rifampicin, pyrazinamide and ethambutol at standard doses given once daily for 8 weeks, continued with RIF and INH at standard doses for 18 weeks.

    Treatment: Rifampicin, Pyrazinamide, Alpibectir (GSK3729098), Ethambutol (E), and Ethionamide

  • Arm 6 (Stage 3)Treatment being tested

    Pretomanid 200mg, ganfeborole (GSK3036656) 20mg, BTZ-043 1000mg and delpazolid (LCB01-0371) 1200mg; given once daily for 26 weeks

    Treatment: BTZ-043, Ganfeborole (GSK3036656), Delpazolid (LCB01-0371), and Pretomanid (Pa)

  • Arm 7 (Stage 3)Existing treatment, for comparison

    Parallel control arm (2HRZE-4RH)

    Treatment: Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol (E)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multiple-arm, Multiple-stage (MAMS), Phase 2B/C, Open-label, Randomized, Controlled Platform Trial to Evaluate Experimental Arms Including Optimised Use of Existing and Introduction of Novel Anti-tuberculosis Drugs, in Adults With Newly Diagnosed, Drug-sensitive, Smear-positive Pulmonary Tuberculosis
Plain-language title
Tests new and existing drugs for newly diagnosed drug-sensitive lung tuberculosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT05807399, who can take part
Record updated
7 October 2025